Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Data availability

Data to support the findings of this research can be made available by the corresponding author upon reasonable request.


  1. Kuehn BM. The Promise and Challenges of CAR-T Gene Therapy. JAMA. 2017;318:2167–9.

    Article  PubMed  Google Scholar 

  2. Treatment Centers Authorized to Administer CAR T Cell Therapy—The ASCO Post [Internet]. [cited 2021 Nov 28]. Available from:

  3. Mian A, Wei W, Winter AM, Khouri J, Jagadeesh D, Anwer F, et al. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leuk Lymphoma. 2021;62:1344–52.

  4. Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132:91.

    Article  Google Scholar 

  5. Azoulay E, Shimabukuro-Vornhagen A, Darmon M, von Bergwelt-Baildon M. Critical care management of chimeric antigen receptor T cell-related toxicity. be aware and prepared. Am J Respir Crit Care Med. 2019;200:20–3.

    Article  PubMed  Google Scholar 

  6. Bach PB. National coverage analysis of CAR-T therapies—policy, evidence, and payment. N Engl J Med. 2018;379:1396–8.

    Article  PubMed  Google Scholar 

  7. Kilgore KM, Mohammadi I, Schroeder A, Teigland C, Purdum AG, Shah GL. Medicare patients receiving chimeric antigen receptor T-cell therapy for Non-Hodgkin lymphoma: a real-world look at patient characteristics, healthcare utilization and costs. Biol Blood Marrow Transpl. 2020;26:S43–4.

    Article  Google Scholar 

  8. Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3:e202072.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Shah GL, Park J, Sauter CS, Duck E, Halton E, Batlevi CW. et al. Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies. Biol Blood Marrow Transpl. 2019;25 Suppl 3:S38–9.

    Article  Google Scholar 

  10. Brown ART, Jindani I, Melancon J, Erfe R, Westin J, Feng L, et al. ICU resource use in critically III patients following chimeric antigen receptor T-cell therapy. Am J Respir Crit Care Med. 2020;202:1184–7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38.

    Article  CAS  Google Scholar 

  13. Ballen KK, Joffe S, Brazauskas R, Wang Z, Aljurf MD, Akpek G, et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources. Biol Blood Marrow Transpl. 2014;20:1819–27.

    Article  Google Scholar 

  14. Harris AH, Hohmann S, Shippey E, Epting G. Quality and cost outcomes in chimeric antigen receptor T-cell immunotherapy in adult large B-Cell cancer patients from the vizient clinical database. Biol Blood Marrow Transpl. 2020;26 Suppl 3:S316–7.

    Article  Google Scholar 

  15. Riedell PA, Walling C, Nastoupil LJ, Pennisi M, Maziarz RT, McGuirk JP, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Biol Blood Marrow Transpl. 2020;26:S41–2.

    Article  Google Scholar 

  16. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.

    Article  CAS  PubMed  Google Scholar 

  18. Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transpl Cell Ther. 2021;27:222–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations



AM collected clinical information, interpreted results, and wrote the manuscript. WW performed statistical analysis. NSM conceived the research and edited the manuscript drafts. All other authors edited and reviewed the final manuscript prior to submission.

Corresponding author

Correspondence to Navneet S. Majhail.

Ethics declarations

Competing interests

NSM serves as a consultant for Anthem, Inc. BTH and PFC have received research funding and consulting feeds from Kite/Gilead and Novartis. AM received funding from ASH HONORS Grant for year 2022–2023.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mian, A., Wei, W., Hamilton, B.K. et al. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. Bone Marrow Transplant 58, 590–593 (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links